Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ immunology
Combined Modality Therapy
Cytokines
/ metabolism
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunotherapy, Adoptive
/ adverse effects
Male
Membrane Proteins
/ antagonists & inhibitors
Middle Aged
Multiple Myeloma
/ immunology
Receptors, Antigen, T-Cell
/ genetics
Receptors, Chimeric Antigen
/ genetics
T-Lymphocytes
/ immunology
Transplantation, Autologous
Treatment Outcome
Young Adult
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
09 07 2019
09 07 2019
Historique:
received:
24
03
2019
accepted:
14
05
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
10
7
2020
Statut:
ppublish
Résumé
This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer antigens New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and L-antigen family member 1 (LAGE-1) and presented by HLA-A*02:01. T cells collected from 25 HLA-A*02:01-positive patients with MM expressing NY-ESO-1 and/or LAGE-1 were activated, transduced with self-inactivating lentiviral vector encoding the NY-ESO-1
Identifiants
pubmed: 31289029
pii: bloodadvances.2019000194
doi: 10.1182/bloodadvances.2019000194
pmc: PMC6616263
doi:
Substances chimiques
Antigens, Neoplasm
0
CTAG1B protein, human
0
Cytokines
0
Membrane Proteins
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Banques de données
ClinicalTrials.gov
['NCT01352286']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2022-2034Informations de copyright
© 2019 by The American Society of Hematology.
Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Nat Biotechnol. 2005 Mar;23(3):349-54
pubmed: 15723046
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Blood. 2017 Dec 14;130(24):2594-2602
pubmed: 28928126
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
FASEB J. 1992 Dec;6(15):3370-8
pubmed: 1464371
Haematologica. 2011 Nov;96(11):1662-9
pubmed: 21791470
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
J Immunol. 2015 Aug 1;195(3):755-61
pubmed: 26188068
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8
pubmed: 25414323
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
PLoS One. 2012;7(7):e41074
pubmed: 22859966
Cancer Immun. 2008 Feb 01;8:2
pubmed: 18237105
J Immunol. 2008 May 1;180(9):6116-31
pubmed: 18424733
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
Clin Cancer Res. 2009 Jul 1;15(13):4499-507
pubmed: 19509133
Int J Cancer. 1998 Jun 10;76(6):903-8
pubmed: 9626360
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Blood. 1999 Aug 15;94(4):1156-64
pubmed: 10438702
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Blood. 2005 May 15;105(10):3939-44
pubmed: 15671442
J Immunol. 1999 Jul 1;163(1):507-13
pubmed: 10384155